Argus Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) had its price target lifted by research analysts at Argus from $145.00 to $170.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Argus’ target price would indicate a potential upside of 12.83% from the stock’s previous close.

Several other brokerages have also recently weighed in on MRK. Barclays upped their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Wells Fargo & Company raised their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Scotiabank upped their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, June 30th. Finally, CICC Research assumed coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.35.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $150.67 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $371.73 billion, a price-to-earnings ratio of 120.54, a PEG ratio of 6.40 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $154.49. The firm’s 50-day moving average is $128.81 and its 200 day moving average is $121.53.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period last year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. The trade was a 24.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Richard R. Deluca sold 20,784 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $130.43, for a total value of $2,710,857.12. Following the sale, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of institutional investors and hedge funds have recently modified their holdings of the company. Round Rock Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 0.7% during the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock worth $1,272,000 after purchasing an additional 66 shares during the last quarter. Cascade Financial Partners LLC grew its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after purchasing an additional 80 shares during the period. Somerset Trust Co grew its position in Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after purchasing an additional 81 shares during the period. Stonebridge Financial Group LLC raised its stake in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after buying an additional 81 shares during the last quarter. Finally, Stronghold Wealth Management L.L.C. lifted its holdings in shares of Merck & Co., Inc. by 2.6% in the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after buying an additional 82 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.